暂无摘要。

暂无摘要。

According to the Kidney disease outcomes quality initiative (K/DOQI) guideline, in order to decrease risk of beta2-microglobulin amyloidosis, noncuprophane (EVIDENCE), high-flux dialyzers (OPINION) should be used. No currently available therapy, except kidney transplantation, can stop disease progression of beta2-microglobulin amyloidosis or provide symptomatic relief (EVIDENCE). Screening for beta2-microglobulin amyloidosis, including measurement of serum levels of beta2-microglobulin, is not recommended (OPINION).

This presentation represents consensus recommendations on prognostic markers and criteria to initiate therapy in patients with Waldenstrom\'s macroglobulinemia (WM), which were prepared in conjunction with the Second International Workshop held in Athens, Greece during September 2002. The panel recommended that initiation of therapy should not be based on the IgM level per se since this may not correlate with the clinical manifestations of WM. The consensus panel agreed that initiation of therapy was appropriate for patients with constitutional symptoms such as recurrent fever, night sweats, fatigue due to anemia, or weight loss. The presence of progressive, symptomatic lymphadenopathy or splenomegaly provide additional reasons to begin therapy. The presence of anemia with a hemoglobin value of